Safety Policies & Visitor Guidelines |
Appointments & Scheduling |
Schedule a COVID vaccine appointment:
call us 8am to 5pm, Monday through Friday, at 267-758-4902.
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Perelman Center for Advanced Medicine
West Pavilion, 1st Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown below from a 3rd party vendor, Press Ganey and as of 7/01/21, our internal platform, PMX Feedback. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
J. Gray, J.C. Thompson, E.L. Carpenter. E. Elkhouly, C. Aggarwal: Plasma cell-free DNA genotyping-from emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer The Oncologist : 2021.
J.C Thompson*, E.L. Carpenter*, B.A. Silva, J. Rosenstein, A.L. Chien, K.J. Quin, C.R. Espenschied, A. Mak, L.A. Kiedrowski, M. Lefterova, R.J. Nagy, S.S. Yee, T. Black, A.P. Singh, C.A. Ciunci, J.M. Bauml, R.B. Cohen, C.J. Langer, C. Aggarwal: Serial monitoring of circulating tumor DNA by next generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy JCO Precision Oncology : 2021 .
Yousefi, M. LaRiviere, E. Cohen, T. Buckingham, S. Yee, T. Black, A.Chien, P. Noel, W. Hwang, S.I. Katz, C. Aggarwal, J.C. Thompson, E.L. Carpenter, D: Non-invasive radiogenomic phenotypes of non-small cell lung cancer predict response to EGFR inhibitors: Preliminary study combining radiomics with liquid biopsy data. Scientific Reports : 2021.
J.C. Thompson, C. Davis, C. Deshpande, W. Hwang, S. Jeffries, A. Huang, T.C. Mitchell, C.J. Langer, S.M. Albelda: A gene signature of antigen processing and presentation machinery (APM) predicts response to checkpoint blockade in Non-Small Cell Lung Cancer (NSCLC) and melanoma Journal for ImmunoTherapy of Cancer : 2020.
C. Aggarwal, J.C Thompson, A. Chien, K. Quin, W. Hwang, T. Black, S.S. Yee, T. Christensen, M. LaRiviere, B. Silva, K. Banks, R. Nagy, E. Helman, A. Berman, C.A. Ciunci, A. Singh, J. Wasser, J.M. Bauml, C.J. Langer, R. B. Cohen, E.L. Carpenter: Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer Clinical Cancer Research : 2020.
J. Kargl, X. Zhu, H. Zhang, G. Yang, T. Riesen, M. Shipley, D. Maeda, J. Zebala, J. Mckay-Fleisch, G. Meredith, A. Mashadi-Hossein, C. Baik, R.H. Pierce, M.W. Redman, J.C. Thompson, S.M. Albelda, H. Bolouri, A.M. Houghton: Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC JCI Insight : 2019.
Klampatsa S. O’Brien, J. C. Thompson, S. A.S. Rao, J.E. Standalick, M. Martinez, M. Liousia, E. Cantu, K. Cengel, E. Moon E, S. Singhal, E.B. Eruslanov, S.M Albelda: Phenotypic and Functional Analysis of Malignant Mesothelioma Tumor-Infiltrating Lymphocytes (TILs) Oncoimmunology : 2019.
C. Aggarwal*, J.C Thompson*, T. Black, S. Katz, R. Fan, S.S Yee, A. Chien, T.L. Evans, J. Bauml, E. Alley, C. Ciunci, A. Berman, R. Cohen, D. Lieberman, K. Majmundar, S.L Savitch, J.D. Morrissette, W. Hwang, K. Elenitoba-Johnson, C.J. Langer, E.L. Carpenter.: Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer. JAMA Oncology 5 (2): 173-180,2019.
S.M Obrien, A. Klampatsa, J.C.Thompson, M. Martinez, W. Hwang, A. Rao, J. Standalick, S. Kim, E. Cantu, L. Litzky, S. Singhal, E. Eruslanov, E.K. Moon, S.M. Albelda: Function of Human Tumor Infiltrating Lymphocytes in Early Stage Non-Small Cell Lung Cancer Cancer Immunology Research : 2019.
J.C. Thompson, W. Hwang, C. Davis, C. Deshpande, S. Jeffries, Y. Rajpurohit, V. Krishna, D. Smirnov, R. Verona, M.V. Lorenzi, C.J. Langer, S.M. Albelda: Gene Signatures of Tumor Inflammation and Epithelial-to-Mesenchymal Transition (EMT) Predict Responses to Immune Checkpoint Blockade in Lung Cancer with High Accuracy Lung Cancer : 2019.
J.C. Thompson, R. Fan, T. Black, G.H. Yu, S.L. Savitch, A. Chien, S. Yee, M. Sen, W. Hwang, S.I. Katz, M. Feldman, A. Vachani, E.L. Carpenter.: Measurement and Immunophenotyping of pleural EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer 127 : 25-33,2019.
C. Aggarwal, C. Davis, R. Mick, J.C. Thompson, S. Ahmed, S. Jeffries, S. Bagley, P. Gabriel, T.L. Evans, J. Bauml, C. Ciunci, E. Alley, J.D. Morrissette, R. Cohen, E.L. Carpenter, C. Langer: Influence of TP53 Mutation on Survival and Transformation to Small Cell Lung Cancer in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer JCO Precision Oncology published on line : 2018.
M. Marmarelis, E. Bange, W. Hwang, Y. Yang, J.C. Thompson, J. Rosenbaum, J. Bauml, C.Ciunci, E. Alley, R. Cohen, C. Langer, E. Carpenter, C. Aggarwal: Impact of KRAS and TP53 co-mutations on outcomes following first-line systemic among patient with STK11 mutated advanced NSCLC JCO Precision Oncology : 2019.
M. Marmarelis, J.C. Thompson, C. Aggarwal, T.L. Evans, E. Carpenter. R.B. Cohen, C.J. Langer, J. Bauml.: Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.
Ann Transl Med.
5 (18): 380,2017.
S. Katz, M. Hammer, S.J. Bagley, C. Aggarwal, J. Bauml, J.C. Thompson, A.C. Nachiappan, C.B. Simone, C. Langer.: Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small lung cancer. J Thorac Oncol.
13 (7): 978-986,2018.
S.J. Bagley, S. Kothari, C. Aggarwal, J. Bauml, E. Alley, T.L Evans, J.A. Kosteva, C. Ciunci, J.C. Thompson, S. Stonehouse-Lee, V.E. Sherry, E. Gilbert, B. Sandy, F. Mutale, G. DiLullo, R.B. Cohen, A. Vachani, C. Langer.: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab treated patients with advanced non-small cell lung cancer. Lung Cancer 106 : 1-7,2017.
J. C. Thompson, S.S Yee, A.B. Troxel, S.L. Savitch, R. Fan, D. Balli, D.B. Lieberman, J.D Morrissette, T.L Evans, J. Bauml, C. Aggarwal, J.A Kosteva, E. Alley, C. Ciunci, R.B. Cohen, S. Bagley, S. Stonehouse-Lee, V.E. Sherry, E. Gilbert, C. Langer, A. Vachani, E. Carpenter: Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clinical Cancer Research 22 (23): 5772-5782,2016.
221 Stemmler Hall3450 Hamilton Walk
Patient appointments: 800-789-7366